Please login to the form below

Not currently logged in
Email:
Password:

MYSTIC trial

This page shows the latest MYSTIC trial news and features for those working in and with pharma, biotech and healthcare.

Innate Pharma and AstraZeneca take monalizumab into phase 3

Innate Pharma and AstraZeneca take monalizumab into phase 3

The trial is set to begin in 2020, depending on regulatory and compliance approvals. ... However, the drug also failed to hit the first of two primary endpoints in the MYSTIC trial of Imfinzi plus AZ’s experimental CTLA4 inhibitor tremelimumab in

Latest news

  • AZ’s Imfinzi combo bombs again in non-small cell lung cancer AZ’s Imfinzi combo bombs again in non-small cell lung cancer

    The same combination failed to move the needle in the MYSTIC trial, but signs of an improvement in a subgroup of patients with a particular cancer biomarker – high tumour mutational burden ... Meanwhile, the PEARL trial is pitting Imfinzi against

  • AZ to address Imfinzi setback, but sees potential with Tagrisso AZ to address Imfinzi setback, but sees potential with Tagrisso

    During the MYSTIC trial, Imfinzi failed to hit the mark on progression-free survival and overall survival endpoints, but AstraZeneca said it would try the drug’s luck as a monotherapy ... However, AZ has confirmed that Imfinzi did demonstrate clinical

  • AZ still sees route to approval for Imfinzi in MYSTIC trial AZ still sees route to approval for Imfinzi in MYSTIC trial

    expand and tweak the protocol of its ongoing NEPTUNE trial of Imfinzi with tremelimumab in first-line NSCLC that is due to generate results early next year. ... month and it is hard to explain why the duo performed worse than Imfinzi on its own in MYSTIC.

  • Is AstraZeneca looking for its next CEO? Is AstraZeneca looking for its next CEO?

    The rumour has surfaced just days after the company confirmed that its immuno-oncology (IO) combination trial MYSTIC (twinning Imfinzi with CTLA4 candidate tremelimumab) failed to outperform chemo in overall survival

  • AZ’s MYSTIC survival data is in – and it’s a bust AZ’s MYSTIC survival data is in – and it’s a bust

    Imfinzi failed to achieve OS improvement. AstraZeneca has released the overall survival (OS) data from its MYSTIC trial of Imfinzi and tremelimumab in advanced non-small cell lung cancer (NSCLC), and

More from news
Approximately 1 fully matching, plus 24 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    The NELSON trial, which looked at screening in Europe, was presented at the recent World Conference on Lung Cancer. ... However, recent overall survival results from the MYSTIC trial, which studied Imfinzi with CTLA4 inhibitor tremelimumab, have just

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    Open-minded culture. Like the new HQ’s construction, there have been setbacks – such as the setback to its Imfinzi tremelimumab immunotherapy combination in the MYSTIC lung cancer trial last year –

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics